Mid-Season Influenza Vaccine Effectiveness Estimates Among DOD Populations: A Composite of Data Presented at VRBPAC—the Vaccines and Related Biological Products Advisory Committee—2024 Meeting on Influenza Vaccine Strain Selection for the 2024-2025 Influenza Season

Image of 48088663. The Department of Defense participates in the annual Vaccines and Related Biological Products Advisory Committee meeting by presenting its mid-season influenza data.

Each March, the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Agency meets to review and discuss data on influenza strain circulation and vaccine effectiveness estimates for the current influenza season.1 The committee then makes recommendations on the selection of strains for the influenza vaccines to be developed for the following influenza season. 

The Department of Defense participates in the VRBPAC meeting by presenting mid-season influenza data from the DOD’s global influenza surveillance, VE, and phylogenetic analyses, in addition to antigenic characterization of circulating viruses. DOD VE analyses are conducted among both service member and non-service member beneficiary populations to complement U.S. population VE estimates.2 

Timing of these analyses is dependent upon the timing of peak activity for each season. Typically, mid-season estimates cannot be generated until February, to allow for adequate testing and sufficient case numbers to provide a reliable sample size for analysis.

These DOD VE analyses represent a joint effort between the Defense Health Agency's Defense Centers for Public Health in Falls Church and Dayton and the Naval Health Research Center. The combined assessment of data from these organizations provides the DOD, FDA, and U.S. Centers for Disease Control with comprehensive mid-season information on how well the influenza vaccines are working for force health protection and the broader military health population. 

MSMR anticipates publishing these findings annually, in February or March, to disseminate this information more widely to interested individuals and public health agencies. 

Author Affiliations

Epidemiology and Analysis Branch, Armed Forces Health Surveillance Division, Defense Health Agency: Dr. Eick-Cost, Ms. Hu; Defense Centers for Public Health–Dayton, Defense Health Agency: Mr. Thervil, Ms. DeMarcus 

Disclaimer

The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, assertions, opinions, nor policies of the Defense Health Agency or the Department of Defense. 

References

  1. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-may-16-2024-meeting-announcement 
  2. McLean HQ, Petrie JG, Hanson KE, et al. Interim estimates of 2022-23 seasonal influenza vaccine effectiveness–Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023;72:201-205.

You also may be interested in...

Topic
April 30, 2026

Medical Surveillance Monthly Report

The Medical Surveillance Monthly Report, a peer-reviewed journal launched in 1995, is the Armed Forces Health Surveillance Division's flagship publication. The MSMR provides monthly evidence-based estimates of the incidence, distribution, impact, and trends of health-related conditions among service members.

Report
March 1, 2026

MSMR Vol. 33 No. 3 - March 2026

.PDF | 1.78 MB

The March 2026 MSMR features two full reports and a Surveillance Snapshot, beginning with a report on mortality rates among U.S. service members, from 2010 to 2020; followed by a report on the incidence and burden of endometriosis among U.S. active component service women, 2017 to 2024; with a Surveillance Snapshot on mid-year populations by sex, age, ...

Article
Feb. 1, 2026

Number of tuberculosis tests and diagnoses of latent tuberculosis infection among U.S. Army active component service members, January 2014–December 2023

This report describes the trends of tuberculosis testing and latent tuberculosis infection positivity in U.S. Army active component soldiers during the first decade following the 2013 U.S. Army Medical Command policy revision to a targeted, risk-based tuberculosis testing strategy.

Article
Feb. 1, 2026

Historical perspective: Post-infection symptoms in U.S. soldiers with malaria during the Second World War: major limitation to return to duty

This historical review discusses how the primary challenge presented by malaria infections in the Pacific theater during World War II was an inability to return recovered soldiers quickly to their units, with nearly one percent of malaria patients repatriated for ‘chronic malaria’.

Report
Feb. 1, 2026

MSMR Vol. 33 No. 2 - February 2026

.PDF | 1.29 MB

The February 2026 MSMR features a report on the number of tuberculosis tests and diagnoses of latent tuberculosis infection in the U.S. Army; a historical review on post-infection symptoms in U.S. soldiers with malaria during World War II and its major limitation to return to duty; a Surveillance Snapshot on adherence to disease and injury ...

Article
Jan. 1, 2026

Case report: An atypical Ross River Virus infection in an Australian Army service member

This case report details the process of differential diagnosis of Ross River virus in an individual diagnosed in Queensland, Australia in 2024. The report demonstrates the need for better clinical awareness among medical care providers for U.S. service members presenting with febrile illness or joint pain following deployment to Australia.

Refine your search